VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
1.860
+0.030 (1.64%)
Mar 9, 2026, 3:23 PM EDT - Market open
VivoSim Labs Employees
VivoSim Labs had 13 employees as of March 31, 2025. The number of employees decreased by 7 or -35.00% compared to the previous year.
Employees
13
Change (1Y)
-7
Growth (1Y)
-35.00%
Revenue / Employee
$10,143
Profits / Employee
-$87,643
Market Cap
4.85M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Lunai Bioworks | 29 |
| GeoVax Labs | 17 |
| Genprex | 13 |
| BioRestorative Therapies | 11 |
| Revelation Biosciences | 9 |
| MetaVia | 9 |
| Acurx Pharmaceuticals | 4 |
| Xenetic Biosciences | 2 |
VIVS News
- 6 days ago - VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales - GlobeNewsWire
- 26 days ago - VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego - GlobeNewsWire
- 5 weeks ago - VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China - GlobeNewsWire
- 2 months ago - VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer - GlobeNewsWire
- 7 months ago - VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer - GlobeNewsWire
- 10 months ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 10 months ago - VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - GlobeNewsWire
- 10 months ago - VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - GlobeNewsWire